Medigen Vaccine Biologics Corporation

Taipei Exchange 6547.TWO

Medigen Vaccine Biologics Corporation Gross Profit Margin for the year ending December 31, 2023: 59.09%

Medigen Vaccine Biologics Corporation Gross Profit Margin is 59.09% for the year ending December 31, 2023, a 201.46% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Medigen Vaccine Biologics Corporation Gross Profit Margin for the year ending December 31, 2022 was -58.24%, a -182.90% change year over year.
Medigen Vaccine Biologics Corporation Gross Profit Margin for the year ending December 31, 2021 was 70.25%, a 5.87% change year over year.
Medigen Vaccine Biologics Corporation Gross Profit Margin for the year ending December 31, 2020 was 66.36%, a -33.64% change year over year.
Medigen Vaccine Biologics Corporation Gross Profit Margin for the year ending December 31, 2019 was 100.00%.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

Taipei Exchange: 6547.TWO

Medigen Vaccine Biologics Corporation

CEO	Leo Lee
IPO Date	Sept. 16, 2015
Location	Taiwan
Headquarters	No. 16, Hu Road
Employees	103
Sector	Health Care
Industries Biotechnology Pharmaceuticals Vaccines

Description

Medigen Vaccine Biologics Corporation, a biotechnology drug company, focuses on the development and production of vaccines and biologics in Taiwan and internationally. The company is developing enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection; influenza vaccine, which has completed Phase III clinical trial to treat influenza; dengue vaccine, which has completed Phase II clinical trial for the treatment of dengue fever; respiratory cell fusion virus (RSV) antibody, which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19- severe special infectious pneumonia. Medigen Vaccine Biologics Corporation was founded in 2012 and is based in Taipei, Taiwan. Medigen Vaccine Biologics Corporation is a subsidiary of Medigen Biotechnology Corp.

Key trends

Past 5 years